bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a report released on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

A number of other research firms have also weighed in on BLUE. Baird R W lowered bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. Wells Fargo & Company reduced their target price on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. Finally, Barclays reduced their target price on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, March 31st. One analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $44.60.

bluebird bio Stock Performance

Shares of BLUE stock opened at $4.95 on Friday. bluebird bio has a 12 month low of $3.56 and a 12 month high of $28.60. The firm has a market capitalization of $48.46 million, a PE ratio of -0.13 and a beta of 0.41. The firm has a fifty day simple moving average of $5.23 and a two-hundred day simple moving average of $7.53. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37.

Institutional Trading of bluebird bio

A number of hedge funds have recently made changes to their positions in BLUE. BNP Paribas Financial Markets increased its position in shares of bluebird bio by 2,270.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 355,562 shares during the last quarter. FMR LLC raised its stake in shares of bluebird bio by 8.1% during the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after acquiring an additional 186,903 shares in the last quarter. Barclays PLC lifted its holdings in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 184,605 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after purchasing an additional 166,771 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of bluebird bio during the 3rd quarter valued at $42,000. 87.43% of the stock is owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.